165 related articles for article (PubMed ID: 27779692)
1. Angiomotin promotes the malignant potential of colon cancer cells by activating the YAP-ERK/PI3K-AKT signaling pathway.
Zhang Y; Yuan J; Zhang X; Yan F; Huang M; Wang T; Zheng X; Zhang M
Oncol Rep; 2016 Dec; 36(6):3619-3626. PubMed ID: 27779692
[TBL] [Abstract][Full Text] [Related]
2. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.
Hsu YL; Hung JY; Chou SH; Huang MS; Tsai MJ; Lin YS; Chiang SY; Ho YW; Wu CY; Kuo PL
Oncogene; 2015 Jul; 34(31):4056-68. PubMed ID: 25381822
[TBL] [Abstract][Full Text] [Related]
3. Angiomotin promotes breast cancer cell proliferation and invasion.
Lv M; Lv M; Chen L; Qin T; Zhang X; Liu P; Yang J
Oncol Rep; 2015 Apr; 33(4):1938-46. PubMed ID: 25647626
[TBL] [Abstract][Full Text] [Related]
4. Angiomotin Family Members: Oncogenes or Tumor Suppressors?
Lv M; Shen Y; Yang J; Li S; Wang B; Chen Z; Li P; Liu P; Yang J
Int J Biol Sci; 2017; 13(6):772-781. PubMed ID: 28656002
[TBL] [Abstract][Full Text] [Related]
5. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway.
Zeng H; Ortiz A; Shen PF; Cheng CJ; Lee YC; Yu G; Lin SC; Creighton CJ; Yu-Lee LY; Lin SH
Oncotarget; 2017 Feb; 8(6):10145-10160. PubMed ID: 28052036
[TBL] [Abstract][Full Text] [Related]
6. Angiomotin promotes renal epithelial and carcinoma cell proliferation by retaining the nuclear YAP.
Lv M; Li S; Luo C; Zhang X; Shen Y; Sui YX; Wang F; Wang X; Yang J; Liu P; Yang J
Oncotarget; 2016 Mar; 7(11):12393-403. PubMed ID: 26848622
[TBL] [Abstract][Full Text] [Related]
7. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.
Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL
Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254
[TBL] [Abstract][Full Text] [Related]
8. Regulation of localization and function of the transcriptional co-activator YAP by angiomotin.
Moleirinho S; Hoxha S; Mandati V; Curtale G; Troutman S; Ehmer U; Kissil JL
Elife; 2017 May; 6():. PubMed ID: 28464980
[TBL] [Abstract][Full Text] [Related]
9. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
10. AMOT is required for YAP function in high glucose induced liver malignancy.
Liu Y; Lu Z; Shi Y; Sun F
Biochem Biophys Res Commun; 2018 Jan; 495(1):1555-1561. PubMed ID: 29217192
[TBL] [Abstract][Full Text] [Related]
11. Angiomotin'g YAP into the nucleus for cell proliferation and cancer development.
Hong W
Sci Signal; 2013 Sep; 6(291):pe27. PubMed ID: 24003252
[TBL] [Abstract][Full Text] [Related]
12. Loss of tricellular tight junction protein LSR promotes cell invasion and migration via upregulation of TEAD1/AREG in human endometrial cancer.
Shimada H; Abe S; Kohno T; Satohisa S; Konno T; Takahashi S; Hatakeyama T; Arimoto C; Kakuki T; Kaneko Y; Takano KI; Saito T; Kojima T
Sci Rep; 2017 Jan; 7():37049. PubMed ID: 28071680
[TBL] [Abstract][Full Text] [Related]
13. Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer.
Ling HH; Kuo CC; Lin BX; Huang YH; Lin CW
Exp Cell Res; 2017 Jan; 350(1):218-225. PubMed ID: 27914787
[TBL] [Abstract][Full Text] [Related]
14. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
Wang W; Li N; Li X; Tran MK; Han X; Chen J
Cell Rep; 2015 Oct; 13(3):524-532. PubMed ID: 26456820
[TBL] [Abstract][Full Text] [Related]
15. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.
Wang J; Wang H; Zhang Y; Zhen N; Zhang L; Qiao Y; Weng W; Liu X; Ma L; Xiao W; Yu W; Chu Q; Pan Q; Sun F
Cell Signal; 2014 May; 26(5):1048-59. PubMed ID: 24468535
[TBL] [Abstract][Full Text] [Related]
16. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner.
Liu Y; Wang G; Yang Y; Mei Z; Liang Z; Cui A; Wu T; Liu CY; Cui L
Oncogene; 2016 May; 35(21):2789-800. PubMed ID: 26387538
[TBL] [Abstract][Full Text] [Related]
17. VASN promotes colorectal cancer progression by activating the YAP/TAZ and AKT signaling pathways via YAP.
Liang W; Zuo J; Liu M; Su Y; Guo B; Hou J; Xing Q; Peng Y; Fang L; Cao Y; Shan J; Sun R; Zhao J; Wang J
FASEB J; 2023 Jan; 37(1):e22688. PubMed ID: 36468780
[TBL] [Abstract][Full Text] [Related]
18. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
19. STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways.
Chen B; Zeng X; He Y; Wang X; Liang Z; Liu J; Zhang P; Zhu H; Xu N; Liang S
Oncotarget; 2016 Nov; 7(44):71400-71416. PubMed ID: 27662663
[TBL] [Abstract][Full Text] [Related]
20. YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
Wang C; Gu C; Jeong KJ; Zhang D; Guo W; Lu Y; Ju Z; Panupinthu N; Yang JY; Gagea MM; Ng PK; Zhang F; Mills GB
Cancer Res; 2017 Apr; 77(7):1637-1648. PubMed ID: 28202507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
